FFD

FFD is a novel gallium-68 labeled radiopharmaceutical diagnostic tracer developed for positron emission tomography (PET) imaging of solid tumors. It specifically targets Fibroblast Activation Protein (FAP), a cell-surface serine protease that is highly overexpressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of more than 90% of epithelial cancers, while showing minimal expression in normal tissues. Developed by researchers at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, FFD is a dimeric derivative of the FAP inhibitor (FAPI) scaffold, designed to enhance binding affinity and tumor retention compared to monomeric tracers like FAPI-04. By providing high-contrast imaging of the tumor stroma, [68Ga]Ga-FFD PET/CT is intended to improve the detection, staging, and monitoring of various malignancies, particularly in cases where standard [18F]FDG PET imaging has limited sensitivity. It is currently being evaluated in Phase 1 clinical trials for safety, biodistribution, and diagnostic performance.

Other names

68Ga-DOTA-FAPI-FFD